Process for preparing xpo1 inhibitors and intermediates for use in the preparation of xp01 inhibitors
WO2020198606A1
Biomarkers for selinexor
WO2020092965A1
E2f1 as a biomarker for treatments using xpo1 inhibitors
WO2020051294A1
The combination of xpo1 inhibitors and second agents for the treatment of prostate cancer
EP3397633A1
Nuclear transport modulators and uses thereof
US2019160063A1
Nuclear transport modulators and uses thereof
US2019002448A1
Substituted benzofuranyl and benzoxazolyl compounds and uses thereof
US2019016710A1
Multicyclic compounds and uses thereof
CN108137563A
For (S, E) -3- (6- aminopyridine -3- bases)-N- ((5- (4- (the fluoro- 3- methylpyrrolidin- l- carbonyls of 3-) phenyl) -7- (4- fluorophenyls) benzofuran -2- bases) methyl) acrylamide for the treatment of cancer
US2018244660A1
Cyclopropylderivatives and their use as kinase inhibitors
US2019218207A1
3-(Pyridin-3-yl)-Acrylamide and N-(Pyridin-3-yl)-Acrylamide Derivatives and Their Use as PAK or NAMPT Modulators
US2017369470A1
Cyclic Compounds and Uses Thereof
WO2016025904A1
Polymorphs of selinexor
WO2015042414A1
Multicyclic compounds and methods of using same
BR112015032921A8
substituted benzofuranyl and benzoxazolyl compounds and their uses
CA2915365A1
Nuclear transport modulators and uses thereof
WO2014205393A1
Nuclear transport modulators and uses thereof
US2016016916A1
Exo Olefin-Containing Nuclear Transport Modulators and Uses Thereof
US2016304500A1
Methods of promoting wound healing using CRM1 inhibitors
EP2925750A1
Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof
